Gianpietro C Semenzato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5296757/publications.pdf

Version: 2024-02-01

440 papers 17,694 citations

65 h-index 25787 108 g-index

448 all docs

448 docs citations

448 times ranked 14934 citing authors

#	Article	IF	CITATIONS
1	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. New England Journal of Medicine, 2011, 364, 2305-2315.	27.0	949
2	ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 1999, 16, 149-73.	0.2	736
3	Aberrant Wnt/ \hat{l}^2 -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis. American Journal of Pathology, 2003, 162, 1495-1502.	3.8	625
4	The Lymphoproliferative Disease of Granular Lymphocytes: Updated Criteria for Diagnosis. Blood, 1997, 89, 256-260.	1.4	324
5	Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax, 2011, 66, 144-150.	5.6	247
6	Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis American Journal of Respiratory and Critical Care Medicine, 1994, 149, 655-659.	5.6	239
7	Abnormal Re-epithelialization and Lung Remodeling in Idiopathic Pulmonary Fibrosis: The Role of ΔN-p63. Laboratory Investigation, 2002, 82, 1335-1345.	3.7	200
8	CXCR3 and Its Ligand CXCL10 Are Expressed by Inflammatory Cells Infiltrating Lung Allografts and Mediate Chemotaxis of T Cells at Sites of Rejection. American Journal of Pathology, 2001, 158, 1703-1711.	3.8	195
9	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	192
10	Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. Journal of Immunology, 1997, 158, 5083-6.	0.8	188
11	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	2.9	185
12	The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer, 1987, 60, 2971-2978.	4.1	179
13	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology, 2013, 31, 1442-1449.	1.6	167
14	Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer, 1990, 65, 341-348.	4.1	161
15	The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood, 1997, 89, 256-60.	1.4	154
16	"The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries American Journal of Respiratory and Critical Care Medicine, 1995, 152, 557-564.	5.6	149
17	Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood, 2004, 104, 502-508.	1.4	144
18	Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. American Journal of Medicine, 2004, 116, 194-197.	1.5	138

#	Article	IF	Citations
19	Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells InÂVivo. Cancer Cell, 2017, 31, 516-531.e10.	16.8	138
20	The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. Journal of Clinical Investigation, 1999, 104, 115-121.	8.2	134
21	New pathogenetic insights into the sarcoid granuloma. Current Opinion in Rheumatology, 2000, 12, 71-76.	4.3	128
22	A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. European Journal of Immunology, 1996, 26, 1816-1824.	2.9	126
23	Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood, 2006, 108, 1698-1707.	1.4	123
24	Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. Journal of Immunology, 1998, 161, 6413-20.	0.8	123
25	T Cells in the Myenteric Plexus of Achalasia Patients Show a Skewed TCR Repertoire and React to HSV-1 Antigens. American Journal of Gastroenterology, 2008, 103, 1598-1609.	0.4	120
26	High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. Aids, 1994, 8, 741-746.	2.2	118
27	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	117
28	Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. Journal of Immunology, 1996, 157, 910-8.	0.8	115
29	High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood, 1987, 70, 396-400.	1.4	109
30	Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes Journal of Biological Chemistry, 1986, 261, 2369-2375.	3.4	107
31	Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. British Journal of Cancer, 1987, 55, 427-428.	6.4	106
32	Interleukin-15 Triggers the Proliferation and Cytotoxicity of Granular Lymphocytes in Patients With Lymphoproliferative Disease of Granular Lymphocytes. Blood, 1997, 89, 201-211.	1.4	106
33	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood, 2003, 102, 1797-1805.	1.4	106
34	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	4.1	106
35	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs, 2013, 5, 826-837.	5.2	105
36	Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. Journal of Immunology, 1999, 162, 3926-32.	0.8	101

#	Article	IF	Citations
37	Tumour necrosis factor: a cytokine with multiple biological activities. British Journal of Cancer, 1990, 61, 354-361.	6.4	97
38	Bronchoalveolar lavage and lung histology. Comparative analysis of inflammatory and immunocompetent cells in patients with sarcoidosis and hypersensitivity pneumonitis. The American Review of Respiratory Disease, 1985, 132, 400-4.	2.9	97
39	Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes. Journal of Biological Chemistry, 1986, 261, 2369-75.	3.4	96
40	CXC Chemokines IP-10 and Mig Expression and Direct Migration of Pulmonary CD8 + /CXCR3 + T Cells in the Lungs of Patients with HIV Infection and T-Cell Alveolitis. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1466-1473.	5.6	95
41	Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood, 1987, 70, 1530-1535.	1.4	95
42	The activating form of CD94 receptor complex: CD94 covalently associated with the Kp39 protein that represents the product of the NKG2-C gene. European Journal of Immunology, 1998, 28, 327-338.	2.9	94
43	Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia, 2012, 26, 1174-1179.	7.2	94
44	HIV-1 and the Lung: Infectivity, Pathogenic Mechanisms, and Cellular Immune Responses Taking Place in the Lower Respiratory Tract. The American Review of Respiratory Disease, 1993, 147, 1038-1049.	2.9	88
45	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood, 2013, 121, 3843-3854.	1.4	85
46	CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Modern Pathology, 1999, 12, 1101-6.	5. 5	85
47	Interleukin-15 promotes the growth of leukemic cells of patients with B- cell chronic lymphoproliferative disorders. Blood, 1996, 87, 3327-3335.	1.4	81
48	Role for CXCR6 and Its Ligand CXCL16 in the Pathogenesis of T-Cell Alveolitis in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1290-1298.	5.6	81
49	Redistribution of T Lymphocytes in the Lymph Nodes of Patients with Sarcoidosis. New England Journal of Medicine, 1982, 306, 48-49.	27.0	79
50	T-lymphocytes and cytokines in sarcoidosis. Current Opinion in Pulmonary Medicine, 2002, 8, 435-440.	2.6	79
51	Immunologic evaluation of T chronic lymphocyte leukemia cells: correlations among phenotype, functional activities, and morphology. Blood, 1982, 59, 688-695.	1.4	78
52	Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood, 1983, 62, 1289-1296.	1.4	78
53	Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia. Leukemia, 2013, 27, 1782-1785.	7.2	7 5
54	Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE, 2013, 8, e75280.	2.5	75

#	Article	IF	Citations
55	Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia, 2014, 28, 1134-1136.	7.2	74
56	Cytochemical Study of Thymocytes and T Lymphocytes. British Journal of Haematology, 1980, 44, 577-582.	2.5	73
57	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	1.2	72
58	B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Research, 1997, 57, 4940-7.	0.9	72
59	Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Journal of Clinical Immunology, 1988, 8, 447-452.	3.8	71
60	Phenotypical and Functional Analysis of Bronchoalveolar Lavage Lymphocytes in Patients with HIV Infection. The American Review of Respiratory Disease, 1988, 138, 1609-1615.	2.9	71
61	Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress–Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. Clinical Cancer Research, 2012, 18, 1888-1900.	7.0	71
62	Polymorphism of angiotensin-converting enzyme gene in sarcoidosis American Journal of Respiratory and Critical Care Medicine, 1996, 153, 851-854.	5.6	70
63	THE SOLUBLE INTERLEUKIN-2 RECEPTOR IN HAEMATOLOGICAL DISORDERS. British Journal of Haematology, 1987, 67, 377-380.	2.5	69
64	Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Annals of Oncology, 2012, 23, 1499-1502.	1.2	68
65	CD8+ T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus type 1. Blood, 1995, 85, 2308-2314.	1.4	67
66	$\mbox{\sc i}\mbox{\sc STAT3}\mbox{\sc /i}\mbox{\sc mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget, 2017, 8, 61876-61889.}$	1.8	67
67	Alpha-interferon activates the natural killer system in patients with hairy cell leukemia. Blood, 1986, 68, 293-296.	1.4	66
68	Clinical spectrum of î³Î′+ T cell LGL leukemia: Analysis of 20 cases. Leukemia Research, 2008, 32, 45-48.	0.8	65
69	JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunologic Research, 2014, 58, 61-69.	2.9	65
70	Complement Receptor 1 Gene Polymorphisms in Sarcoidosis. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 17-23.	2.9	64
71	CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells. Clinical Cancer Research, 2004, 10, 964-971.	7.0	64
72	Early effects of the antineoplastic agent salinomycin on mitochondrial function. Cell Death and Disease, 2015, 6, e1930-e1930.	6.3	64

#	Article	IF	CITATIONS
73	Spontaneous Production of Interleukin-6 by Alveolar Macrophages from Human Immunodeficiency Virus Type 1-Infected Patients. Journal of Infectious Diseases, 1992, 166, 731-737.	4.0	63
74	Clonal studies of CD3- lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2363-2368.	1.4	63
75	Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease American Journal of Respiratory and Critical Care Medicine, 1996, 153, 1359-1367.	5.6	63
76	Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica, 2014, 99, 1101-1106.	3.5	63
77	Abnormal expansions of polyclonal large to small size granular lymphocytes: reactive or neoplastic process?. Blood, 1984, 63, 1271-1277.	1.4	62
78	The Mitochondrial Effects of Small Organic Ligands of BCL-2. Journal of Biological Chemistry, 2006, 281, 10066-10072.	3.4	62
79	Immunohistological study in sarcoidosis: Evaluation at different sites of disease activity. Clinical Immunology and Immunopathology, 1984, 30, 29-40.	2.0	59
80	Lung T cells in hypersensitivity pneumonitis: phenotypic and functional analyses. Journal of Immunology, $1986,137,1164-72$.	0.8	59
81	Different Types of Cytotoxic Lymphocytes Recovered from the Lungs of Patients with Hypersensitivity Pneumonitis. The American Review of Respiratory Disease, 1988, 137, 70-74.	2.9	58
82	Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia. Blood, 1985, 66, 1035-1042.	1.4	57
83	Alterations in T cells of cancer-bearers: whence specificity?. Trends in Immunology, 1996, 17, 365-368.	7.5	57
84	Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia, 2007, 21, 965-972.	7.2	57
85	Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2381-2385.	1.4	55
86	Seroreactivity to an Envelope Protein of Human T-Cell Leukemia/Lymphoma Virus in Patients With CD3â^' (Natural Killer) Lymphoproliferative Disease of Granular Lymphocytes. Blood, 1997, 90, 1977-1981.	1.4	55
87	Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia, 2011, 25, 1768-1781.	7.2	55
88	Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. Leukemia, 2017, 31, 292-300.	7.2	55
89	Longitudinal study of alveolitis in hypersensitivity pneumonitis patients: An immunologic evaluation. Journal of Allergy and Clinical Immunology, 1988, 82, 577-585.	2.9	54
90	Immunology of interstitial lung diseases: cellular events taking place in the lung of sarcoidosis, hypersensitivity pneumonitis and HIV infection. European Respiratory Journal, 1991, 4, 94-102.	6.7	54

#	Article	IF	Citations
91	New aspects of hypersensitivity pneumonitis. Current Opinion in Pulmonary Medicine, 2004, 10, 378-382.	2.6	53
92	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood, 2008, 112, 4665-4674.	1.4	53
93	Alveolar Macrophages from Patients with AIDS and AIDS-related Complex Constitutively Synthesize and Release Tumor Necrosis Factor Alpha. The American Review of Respiratory Disease, 1991, 144, 195-201.	2.9	51
94	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. Blood, 1997, 90, 1115-1123.	1.4	51
95	Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood, 1993, 81, 752-758.	1.4	50
96	Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood, 1994, 84, 4249-4256.	1.4	50
97	Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. British Journal of Haematology, 1999, 106, 662-668.	2.5	50
98	S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. Blood, 2012, 120, 4391-4399.	1.4	50
99	Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease. British Journal of Cancer, 1984, 50, 415-417.	6.4	49
100	Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. Annals of Oncology, 2014, 25, 2030-2035.	1.2	49
101	Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia, 2020, 34, 1116-1124.	7.2	49
102	Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients. Clinical and Experimental Immunology, 1984, 57, 331-7.	2.6	49
103	Increased Levels of Soluble Interleukin-2 Receptor in Non-Hodgkin's Lymphomas: Relationship with Clinical, Histologic, and Phenotypic Features. American Journal of Clinical Pathology, 1989, 92, 186-191.	0.7	48
104	The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils. European Journal of Immunology, 2003, 33, 840-849.	2.9	48
105	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica, 2015, 100, e515-e518.	3.5	48
106	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica, 2012, 97, 56-63.	3.5	47
107	CD8 alveolitis in sarcoidosis: Incidence, phenotypic characteristics, and clinical features. American Journal of Medicine, 1993, 95, 466-472.	1.5	46
108	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. Journal of Hematology and Oncology, 2013, 6, 78.	17.0	46

#	Article	IF	Citations
109	Distribution and heterogeneity of cells detected by HNK-1 monoclonal antibody in blood and tissues in normal, reactive and neoplastic conditions. Clinical and Experimental Immunology, 1984, 57, 195-206.	2.6	46
110	Activated T Cells with Immunoregulatory Functions at Different Sites of Involvement in Sarcoidosis Annals of the New York Academy of Sciences, 1986, 465, 56-73.	3.8	45
111	Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood, 1993, 81, 2723-2727.	1.4	45
112	Immune mechanisms in interstitial lung diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2000, 55, 1103-1120.	5.7	45
113	Analysis of the T cell receptor in the lymphoproliferative disease of granular lymphocytes: superantigen activation of clonal CD3+ granular lymphocytes. Cancer Research, 1995, 55, 6140-5.	0.9	45
114	Cells and molecules involved in the development of sarcoid granuloma. Journal of Clinical Immunology, 1998, 18, 184-192.	3.8	44
115	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. British Journal of Haematology, 2007, 138, 594-602.	2.5	44
116	Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e54824.	2.5	44
117	Pulmonary immune cells in health and disease: lymphocytes. European Respiratory Journal, 1993, 6, 1378-401.	6.7	44
118	The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. Journal of Immunology, 1996, 157, 1854-62.	0.8	44
119	Serum levels of tumour necrosis factor- \hat{l}_{\pm} in patients with B-cell chronic lymphocytic leukaemia. European Journal of Cancer, 1994, 30, 1259-1263.	2.8	43
120	Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. Journal of Leukocyte Biology, 2007, 82, 946-955.	3.3	43
121	T-lymphocyte subpopulations in chronic lymphocytic leukemia: A quantitative and functional study. Cancer, 1981, 48, 2191-2197.	4.1	42
122	Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. British Journal of Cancer, 1988, 58, 368-372.	6.4	42
123	Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. American Journal of Pathology, 1993, 143, 1348-55.	3.8	42
124	Prognostic Significance of the Evaluation of Bronchoalveolar Lavage Cell Populations in Patients with HIV-1 Infection and Pulmonary Involvement. Chest, 1991, 100, 1601-1606.	0.8	41
125	ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease. British Journal of Haematology, 1993, 84, 161-162.	2.5	41
126	Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. Cancer Research, 2015, 75, 4153-4163.	0.9	41

#	Article	IF	CITATIONS
127	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal, 2021 , 11 , 4 .	6.2	41
128	Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia, 2007, 21, 1060-1069.	7.2	40
129	Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood, 2015, 125, 3747-3755.	1.4	40
130	Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia. Frontiers in Oncology, 2020, 10, 152.	2.8	40
131	T lymphocytes in B-cell chronic lymphocytic leukemia: Characterization by monoclonal antibodies and correlation with Fc receptors. Clinical Immunology and Immunopathology, 1983, 26, 155-161.	2.0	39
132	Characterization of two patients with lymphomas of large granular lymphocytes. Cancer, 1984, 53, 445-452.	4.1	39
133	HLA Class I, II, and III Polymorphism in Italian Patients With Sarcoidosis. Chest, 1993, 104, 1170-1175.	0.8	39
134	Interleukin-15: A Novel Cytokine with Regulatory Properties on Normal and Neoplastic B Lymphocytes. Leukemia and Lymphoma, 1997, 27, 35-42.	1.3	39
135	Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer, 2010, 10, 526.	2.6	39
136	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget, 2015, 6, 42130-42149.	1.8	39
137	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. Cancers, 2019, 11, 1939.	3.7	39
138	Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood, 1997, 89, 201-11.	1.4	39
139	T-HELPER PHENOTYPE CHRONIC LYMPHOCYTIC LEUKAEMIA AND "ADULT T-CELL LEUKAEMIA" IN ITALY. Lancet, The, 1985, 326, 633-636.	13.7	38
140	Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome. Cancer, 1993, 72, 201-206.	4.1	38
141	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood, 2005, 105, 931-939.	1.4	38
142	Part II: Vaccines for haematological malignant disorders. Lancet Oncology, The, 2004, 5, 727-737.	10.7	37
143	T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. Best Practice and Research in Clinical Haematology, 2019, 32, 207-216.	1.7	37
144	Detection of a Soluble form of the Receptor for Interleukin 2 in the Serum of Patients with Hairy Cell Leukaemia. International Journal of Biological Markers, 1986, 1, 101-104.	1.8	36

#	Article	IF	CITATIONS
145	Pulmonary alveolar macrophages in patients with sarcoidosis and hypersensitivity pneumonitis: Characterization by monoclonal antibodies. Journal of Clinical Immunology, 1987, 7, 64-70.	3.8	36
146	Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. British Journal of Haematology, 2000, 108, 717-723.	2.5	36
147	Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica, 2009, 94, 1341-1345.	3 . 5	36
148	3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 785-794.	2.5	36
149	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1571-1580.	2.2	36
150	Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. Blood, 1990, 75, 1525-1530.	1.4	35
151	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L240-L250.	2.9	35
152	Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation. Microscopy Research and Technique, $2001, 53, 278-287$.	2.2	35
153	Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes. Seminars in Hematology, 2003, 40, 201-212.	3.4	35
154	Biophysical Characterization and Expression Analysis of Kv1.3 Potassium Channel in Primary Human Leukemic B Cells. Cellular Physiology and Biochemistry, 2015, 37, 965-978.	1.6	35
155	Release of granulocyte-macrophage colony-stimulating factor by alveolar macrophages in the lung of HIV-1-infected patients. A mechanism accounting for macrophage and neutrophil accumulation. Journal of Immunology, 1992, 149, 3379-85.	0.8	35
156	Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. Blood, 1990, 76, 2080-2085.	1.4	34
157	Multimarker immunohistochemical staining of calgranulins, chloroacetate esterase, and S100 for simultaneous demonstration of inflammatory cells on paraffin sections Journal of Histochemistry and Cytochemistry, 1990, 38, 1669-1675.	2.5	34
158	HIV and pulmonary immune responses. Trends in Immunology, 1996, 17, 359-364.	7. 5	34
159	Selection of T lymphocytes bearing limited TCR-Vbeta regions in the lung of hypersensitivity pneumonitis and sarcoidosis American Journal of Respiratory and Critical Care Medicine, 1997, 155, 587-596.	5.6	34
160	The Quality of Life of Children and Adolescents with X-Linked Agammaglobulinemia. Journal of Clinical Immunology, 2009, 29, 501-507.	3.8	34
161	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. British Journal of Haematology, 2018, 181, 229-233.	2.5	34
162	Immune effector cells in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 1997, 3, 348-355.	2.6	33

#	Article	IF	Citations
163	Cytokines in sarcoidosis. Seminars in Respiratory Infections, 1998, 13, 184-96.	1.3	33
164	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica, 2014, 99, 881-887.	3.5	32
165	Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Haematologica, 2014, 99, 1069-1077.	3.5	32
166	HSP70/HSF1 axis, regulated <i>via</i> a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 145, 3089-3100.	5.1	32
167	Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. British Journal of Haematology, 1989, 73, 181-186.	2.5	31
168	Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. Journal of Leukocyte Biology, 1995, 58, 495-500.	3.3	31
169	The natural killer-related receptor for HLA-C expressed on T cells from CD3+ lymphoproliferative disease of granular lymphocytes displays either inhibitory or stimulatory function. Blood, 1996, 87, 2369-2375.	1.4	31
170	Towards a new age in the treatment of multiple myeloma. Annals of Hematology, 2007, 86, 159-172.	1.8	31
171	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. British Journal of Cancer, 2019, 121, 150-156.	6.4	31
172	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica, 2022, 107, 868-876.	3.5	31
173	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget, 2015, 6, 6544-6552.	1.8	31
174	Large granular lymphocytosis. Haematologica, 1998, 83, 936-42.	3.5	31
175	Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood, 2005, 106, 3926-3931.	1.4	30
176	The mitochondrial effects of novel apoptogenic molecules generated by psoralen photolysis as a crucial mechanism in PUVA therapy. Blood, 2007, 109, 4988-4994.	1.4	30
177	Inactivation of CK1 $\hat{l}\pm$ in multiple myeloma empowers drug cytotoxicity by affecting AKT and \hat{l}^2 -catenin survival signaling pathways. Oncotarget, 2017, 8, 14604-14619.	1.8	30
178	Heterogeneity of T-CLL defined by monoclonal antibodies in nine patients. Clinical Immunology and Immunopathology, 1982, 24, 330-341.	2.0	29
179	Role of Bronchoalveolar Lavage in Predicting Survival of Patients with Human Immunodeficiency Virus Infection. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1501-1507.	5.6	29
180	HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen. PLoS ONE, 2012, 7, e39902.	2.5	29

#	Article	IF	CITATIONS
181	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Journal of rheumatology Supplement, The, 2015, 93, 48-52.	2.2	29
182	Aberrant expression of $\langle scp \rangle CD \langle scp \rangle 10$ and $\langle scp \rangle BCL \langle scp \rangle 6$ in mantle cell lymphoma. Histopathology, 2017, 71, 769-777.	2.9	29
183	Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. European Journal of Cancer, 2017, 72, 103-111.	2.8	29
184	Pulmonary alveolar macrophages from patients with active sarcoidosis express type IV collagenolytic proteinase. An enzymatic mechanism for influx of mononuclear phagocytes at sites of disease activity Journal of Clinical Investigation, 1989, 84, 605-612.	8.2	29
185	Human Retroviruses and Lung Involvement. The American Review of Respiratory Disease, 1989, 139, 1317-1322.	2.9	28
186	Ifosfamide and Cyclophosphamide: Effects on Immunosurveillance. Oncology, 2003, 65, 17-20.	1.9	28
187	Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3. Leukemia Research, 2013, 37, 221-227.	0.8	28
188	Identification of a <i>miR-146b</i> -Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia. Haematologica, 2020, 105, 1351-1360.	3.5	28
189	High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood, 1987, 70, 396-400.	1.4	28
190	ACCESS: A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 83-6.	0.2	28
191	Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. Clinical Immunology and Immunopathology, 1989, 50, 146-153.	2.0	27
192	\hat{I}^{3} T Cell Receptor Subsets in the Lung of Patients with HIV-1 Infection. Cellular Immunology, 1994, 153, 194-205.	3.0	27
193	NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. Cells, 2020, 9, 768.	4.1	27
194	CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. Respiratory Research, 2005, 6, 20.	3.6	26
195	Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and <scp>L</scp> yn inhibition by nocodazole. British Journal of Haematology, 2014, 165, 659-672.	2.5	26
196	Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia. Blood, 2014, 123, 875-883.	1.4	26
197	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 612-620.e5.	0.4	26
198	High serum levels of soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis, 1987, 4, 25-7.	0.4	26

#	Article	IF	Citations
199	Immunoregulation in sarcoidosis. Clinical Immunology and Immunopathology, 1981, 19, 416-427.	2.0	25
200	Chromosome studies in patients with T-CLL chronic lymphocytic leukemia and expansions of granular lymphocytes. International Journal of Cancer, 1984, 34, 171-176.	5.1	25
201	Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer, 1987, 60, 2412-2418.	4.1	25
202	Impaired cytokine production by neutrophils isolated from patients with AIDS. Aids, 1998, 12, 373-379.	2.2	25
203	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cells–T-Cell Interaction. Blood, 1999, 93, 1277-1286.	1.4	25
204	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. British Journal of Haematology, 2017, 178, 81-93.	2.5	25
205	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 678-685.e4.	0.4	25
206	Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. Leukemia, 2019, 33, 1148-1160.	7.2	25
207	Generation of superoxide anion by alveolar macrophages in sarcoidosis: evidence for the activation of the oxygen metabolism in patients with high-intensity alveolitis. Immunology, 1989, 66, 451-8.	4.4	25
208	HNK-1 monoclonal antibody (Leu-7) in the identification of abnormal expansions of large granular lymphocytes. Clinical and Experimental Immunology, 1983, 52, 641-7.	2.6	25
209	Classification of patients with T-cell chronic lymphocytic leukemia and expansions of granular lymphocytes: Heterogeneity of Italian cases by a multiparameter analysis. Journal of Clinical Immunology, 1984, 4, 174-184.	3.8	24
210	Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. Haematologica, 2010, 95, 1722-1729.	3.5	24
211	Targeting CK2-driven non-oncogene addiction in B-cell tumors. Oncogene, 2016, 35, 6045-6052.	5.9	24
212	BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. British Journal of Haematology, 2019, 185, 193-197.	2.5	24
213	Expression of TNF receptors by T cells and membrane TNF-alpha by alveolar macrophages suggests a role for TNF-alpha in the regulation of the local immune responses in the lung of HIV-1-infected patients. Journal of Immunology, 1995, 154, 2928-38.	0.8	24
214	Serum levels of soluble interleukin-2 receptors in acute and chronic viral hepatitis. Digestive Diseases and Sciences, 1989, 34, 1559-1563.	2.3	23
215	Cell apoptosis and granulomatous lung diseases. Current Opinion in Pulmonary Medicine, 1998, 4, 261-266.	2.6	23
216	B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. Cancer, 2000, 89, 1259-1268.	4.1	23

#	Article	IF	Citations
217	Expression of Receptor for Advanced Glycation End Products in Sarcoid Granulomas. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 498-506.	5.6	23
218	State of the art in natural killer cell malignancies. International Journal of Laboratory Hematology, 2012, 34, 117-128.	1.3	23
219	Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells. Haematologica, 2017, 102, 1401-1412.	3.5	23
220	p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from \hat{l}^2 -arrestin at early endosomes. Oncogene, 2018, 37, 1534-1550.	5.9	23
221	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leukemia Research, 2018, 74, 86-88.	0.8	23
222	Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget, 2017, 8, 110727-110731.	1.8	23
223	Cytotoxic Events Taking Place in the Lung of Patients with HIV-1 Infection: Evidence of an Intrinsic Defect of the Major Histocompatibility Complex-unrestricted Killing Partially Restored by the Incubation with rIL-2. The American Review of Respiratory Disease, 1990, 142, 516-522.	2.9	22
224	Immunological, clinical and molecular aspects of sarcoidosis. Molecular Aspects of Medicine, 1997, 18, 91-165.	6.4	22
225	The growth and the control of human immunodeficiency virus in the lung: implications for highly active antiretroviral therapy. European Journal of Clinical Investigation, 1999, 29, 964-972.	3.4	22
226	Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?. Frontiers in Immunology, 2014, 5, 72.	4.8	22
227	Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. Cell Death Discovery, 2019, 5, 98.	4.7	22
228	Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family. Redox Biology, 2020, 37, 101705.	9.0	22
229	A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. Blood Cancer Journal, 2020, 10, 42.	6.2	22
230	Skewing of the T-cell receptor repertoire in the lung of patients with HIV-1 infection. Aids, 1996, 10, 729-738.	2.2	21
231	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology, 2009, 82, 93-105.	2.2	21
232	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. Haematologica, 2014, 99, 1826-1833.	3.5	21
233	TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis. Clinical and Molecular Allergy, 2015, 13, 16.	1.8	21
234	HTLV-I ANTIBODIES AND LYMPHOPROLIFERATIVE DISEASE OF GRANULAR LYMPHOCYTES. Lancet, The, 1987, 330, 1527.	13.7	20

#	Article	IF	Citations
235	HIV load in highly purified CD8+ T cells retrieved from pulmonary and blood compartments. Journal of Leukocyte Biology, 1998, 64, 298-301.	3.3	20
236	Applied clinical immunology in sarcoidosis. Current Opinion in Pulmonary Medicine, 2002, 8, 441-444.	2.6	20
237	Changes of human B and B-1a peripheral blood lymphocytes with age. Hematology, 2007, 12, 337-341.	1.5	20
238	Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. Blood Cancer Journal, 2018, 8, 51.	6.2	20
239	Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3-(natural killer) lymphoproliferative disease of granular lymphocytes. Blood, 1997, 90, 1977-81.	1.4	20
240	Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clinical Immunology and Immunopathology, 1985, 37, 262-275.	2.0	19
241	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood, 2000, 96, 647-654.	1.4	19
242	Pancreatic Cancer Alters Human CD4+ T Lymphocyte Function. Pancreas, 2011, 40, 1131-1137.	1.1	19
243	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematological Oncology, 2017, 35, 925-928.	1.7	19
244	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer Journal, 2018, 8, 20.	6.2	19
245	<p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p> . OncoTargets and Therapy, 2020, Volume 13, 9679-9688.	2.0	19
246	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	2.5	19
247	Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells. Oncotarget, 2016, 7, 57086-57098.	1.8	19
248	Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood, 1983, 62, 1289-96.	1.4	19
249	Role of tumor necrosis factor-alpha and its specific 55-Kd and 75-Kd receptors in patients with lymphoproliferative disease of granular lymphocytes. Blood, 1992, 80, 2030-2037.	1.4	18
250	IMMUNOLOGIC EFFECTS OF HIV IN THE LUNG. Clinics in Chest Medicine, 1996, 17, 633-645.	2.1	18
251	A Pyrazolo[3,4- <i>d</i>]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. Oncotarget, 2016, 7, 65171-65184.	1.8	18
252	Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood, 1987, 70, 1530-5.	1.4	18

#	Article	IF	CITATIONS
253	Origin of the soluble interleukin-2 receptor in the serum of patients with hairy cell leukemia. Leukemia, 1988, 2, 788-92.	7.2	18
254	The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features. International Journal of Clinical and Laboratory Research, 1992, 22, 133-142.	1.0	17
255	Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor. British Journal of Cancer, 1995, 71, 240-245.	6.4	17
256	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 277-282.	4.1	17
257	Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. Haematologica, 2017, 102, e140-e143.	3.5	17
258	p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. Haematologica, 2019, 104, 2040-2052.	3.5	17
259	Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. Cancer, 1989, 64, 667-672.	4.1	16
260	Lung Lymphocytes: Origin, Biological Functions, and Laboratory Techniques for Their Study in immune-Mediated Pulmonary Disorders. Critical Reviews in Clinical Laboratory Sciences, 1996, 33, 423-455.	6.1	16
261	Detection of Epstein-Barr Virus by PCR Analyses in Lymphoproliferative Disease of Granular Lymphocytes. Leukemia and Lymphoma, 1996, 23, 371-374.	1.3	16
262	Diagnostic and prognostic value of low percentage of glycosylated ferritin in acquired hemophagocytic lymphohistiocytosis: A singleâ€center study. International Journal of Laboratory Hematology, 2017, 39, 620-624.	1.3	16
263	Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. International Journal of Molecular Sciences, 2018, 19, 1512.	4.1	16
264	Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. Hematological Oncology, 2020, 38, 823-826.	1.7	16
265	Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options. Cells, 2021, 10, 2800.	4.1	16
266	Immunohistologic analysis of a human pulmonary alveolar macrophage antigen. Clinical Immunology and Immunopathology, 1985, 37, 213-219.	2.0	15
267	Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes. Cancer, 1989, 64, 2019-2023.	4.1	15
268	Shedding of the soluble form of the CD8 complex by CD8 +/HLA-DR + cells in HIV-1-infected patients. Aids, 1991, 5, 813-820.	2.2	15
269	Antiapoptotic Effects of IL-15 on Pulmonary Tc1 Cells of Patients with Human Immunodeficiency Virus Infection. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 484-489.	5.6	15
270	T cells in the lung of patients with hypersensitivity pneumonitis accumulate in a clonal manner. Journal of Leukocyte Biology, 2004, 75, 798-804.	3.3	15

#	Article	IF	Citations
271	Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30. Experimental Hematology, 2009, 37, 1167-1175.	0.4	15
272	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	1.7	15
273	Identification of novel STAT5B mutations and characterization of $TCR\hat{I}^2$ signatures in CD4+ T-cell large granular lymphocyte leukemia. Blood Cancer Journal, 2022, 12, 31.	6.2	15
274	Spontaneous resolution of p58/EB6 antigen restricted NKâ€ŧype lymphoproliferative disease of granular lymphocytes: role of Epstein Barr virus infection. British Journal of Haematology, 1997, 99, 215-221.	2.5	14
275	T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. Leukemia Research, 2007, 31, 371-377.	0.8	14
276	Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. American Journal of Hematology, 2013, 88, 955-960.	4.1	14
277	Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia, 2014, 28, 2094-2097.	7.2	14
278	Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins. Journal of Leukocyte Biology, 2016, 100, 1061-1070.	3.3	14
279	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer, 2021, 127, 2657-2665.	4.1	14
280	Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?. Translational Medicine @ UniSa, 2014, 8, 4-11.	0.5	14
281	Detection of a soluble form of the receptor for interleukin 2 in the serum of patients with hairy cell leukaemia. International Journal of Biological Markers, 1986, 1, 101-4.	1.8	14
282	Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: Evaluation of cytotoxic events. Leukemia Research, 1987, 11, 843-847.	0.8	13
283	Release of prostaglandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis. Thorax, 1997, 52, 76-83.	5 . 6	13
284	Role of <i>miR-15a/miR-16-1</i> and the <i>TP53</i> axis in regulating telomerase expression in chronic lymphocytic leukemia. Haematologica, 2017, 102, e253-e256.	3.5	13
285	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 508-512.	1.7	13
286	Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients. Leukemia and Lymphoma, 2019, 60, 2067-2070.	1.3	13
287	Infections in Patients with Myelodysplastic Syndrome/Acute Myeloid Leukemia Treated with Azacitidine: Report from a Single Center. Blood, 2014, 124, 5622-5622.	1.4	13
288	The Immunology of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 1986, 8, 17-29.	2.1	12

#	Article	IF	CITATIONS
289	Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. Cellular Immunology, 1992, 141, 253-259.	3.0	12
290	Does analysis of bronchoalveolar lavage fluid provide a tool to monitor disease progression or to predict survival in patients with HIV-1 infection?. Thorax, 1994, 49, 848-851.	5.6	12
291	Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. British Journal of Cancer, 1994, 69, 1046-1051.	6.4	12
292	Immunology of idopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 1996, 2, 364-369.	2.6	12
293	HLA-Gm/kappam interaction in sarcoidosis. Suggestions for a complex genetic structure. European Respiratory Journal, 2000, 16, 74-80.	6.7	12
294	Serum free light chains in the differential diagnosis and prognosis of primary and secondary hypogammaglobulinemia. Journal of Allergy and Clinical Immunology, 2015, 135, 1075-1077.e6.	2.9	12
295	The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells. Oncotarget, 2016, 7, 45429-45443.	1.8	12
296	T-CELL LEUKAEMIA-LYMPHOMA VIRUS AND HETEROGENEITY OF CHRONIC T-CELL MALIGNANCIES. Lancet, The, 1982, 320, 1273.	13.7	11
297	Chronic T-cell leukaemias. III. T-colonies, PHA response and correlation with membrane phenotype. Leukemia Research, 1982, 6, 809-814.	0.8	11
298	CHRONIC LYMPHOCYTOSIS DUE TO THE EXPANSION OF GRANULAR LYMPHOCYTES. British Journal of Haematology, 1985, 60, 771-773.	2.5	11
299	Soluble interleukin-2 receptor in hairy-cell leukemia: a reliable marker of disease. International Journal of Clinical and Laboratory Research, 1993, 23, 34-37.	1.0	11
300	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. British Journal of Haematology, 2005, 130, 878-889.	2.5	11
301	Coexistence of primary AL amyloidosis and POEMS syndrome: Efficacy of melphalanâ€dexamethasone and role of biochemical markers in monitoring the diseases course. American Journal of Hematology, 2010, 85, 131-132.	4.1	11
302	KIR/HLAâ€I mismatching and risk of relapse in paediatric patients undergoing nonâ€haploidentical allogeneic haematopoietic stem cell transplantation. Pediatric Transplantation, 2011, 15, 198-204.	1.0	11
303	EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. Leukemia Research, 2013, 37, 1457-1460.	0.8	11
304	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cells–T-Cell Interaction. Blood, 1999, 93, 1277-1286.	1.4	11
305	Expression and functional role of the p75 interleukin 2 receptor chain on leukemic hairy cells. Cancer Research, 1992, 52, 5223-8.	0.9	11
306	Immune responses in the lung: Basic principles. Lung, 1990, 168, 1001-1012.	3.3	10

#	Article	IF	CITATIONS
307	Bronchoalveolar lavage and the immunology of lung cancer. Lung, 1990, 168, 1041-1049.	3.3	10
308	Clonally expanded CD3+, CD4â^', CD8â^' cells bearing the or the T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes. Clinical Immunology and Immunopathology, 1991, 60, 371-383.	2.0	10
309	Alveolar Macrophages in HIV-1 Infection Express Accessory Molecules, Activation Markers, and Release Increased Biological Response Modifiers. Chest, 1993, 103, 108S-111S.	0.8	10
310	Cheese workers' lung. Allergy: European Journal of Allergy and Clinical Immunology, 1996, 51, 959-960.	5.7	10
311	The Italian quality control study for evaluation of CD4 cells in centres involved in the treatment of HIV-1 patients. Clinical and Experimental Immunology, 1998, 111, 564-573.	2.6	10
312	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	1.8	10
313	GSK-3 Inhibition Modulates Metalloproteases in a Model of Lung Inflammation and Fibrosis. Frontiers in Molecular Biosciences, 2021, 8, 633054.	3.5	10
314	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Current Cancer Drug Targets, 2018, 18, 608-616.	1.6	10
315	Immunologic evaluation of T chronic lymphocyte leukemia cells: correlations among phenotype, functional activities, and morphology. Blood, 1982, 59, 688-95.	1.4	10
316	Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood, 1993, 81, 2723-7.	1.4	10
317	Heterogeneous Expression of Dipeptidyl-Amino-Peptidase (DAP IV) in T-Cell Chronic Lymphocytic Leukemia. Acta Haematologica, 1984, 71, 277-281.	1.4	9
318	Definition by CB12 monoclonal antibody of a differentiation marker specific for human monocytes and their bone marrow precursors. Cellular Immunology, 1986, 97, 276-285.	3.0	9
319	Expression of a functional p75 interleukin-2 receptor on lung lymphocytes from patients with human immunodeficiency virus type 1 (HIV-1) infection. Journal of Clinical Immunology, 1992, 12, 371-380.	3.8	9
320	ILâ€12 is involved in the activation of CD3 + granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 1996, 92, 308-314.	2.5	9
321	Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 2003, 120, 765-773.	2.5	9
322	Impact Factor as Measure of Scientific Quality. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1070-1071.	5.6	9
323	Pulmonary Complications in Patients with Hematological Disorders: Pathobiological Bases and Practical Approach. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 439-444.	2.1	9
324	Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. American Journal of Hematology, 2011, 86, E64-E66.	4.1	9

#	Article	IF	CITATIONS
325	Serum Anti-Heart and Anti-Intercalated Disk Autoantibodies: Novel Autoimmune Markers in Cardiac Sarcoidosis. Journal of Clinical Medicine, 2021, 10, 2476.	2.4	9
326	Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-NaÃ-ve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. Blood, 2018, 132, 5548-5548.	1.4	9
327	Abnormal expansions of polyclonal large to small size granular lymphocytes: reactive or neoplastic process?. Blood, 1984, 63, 1271-7.	1.4	9
328	Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood, 1994, 84, 4249-56.	1.4	9
329	Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2381-5.	1.4	9
330	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia, 2022, 36, 1947-1950.	7.2	9
331	Binding of sheep erythrocytes in chronic lymphocytic leukemias of B-cell origin. Journal of Clinical Immunology, 1982, 2, 296-302.	3.8	8
332	Rearrangement for the T-cell receptor gene and co-expression of immature T-cell markers and natural killer cell phenotype, in a patient with acute lymphoblastic leukaemia. British Journal of Haematology, 1987, 65, 17-22.	2.5	8
333	Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes. Journal of Clinical Immunology, 1989, 9, 401-408.	3.8	8
334	Immunopathology of ocular sarcoidosis. International Ophthalmology, 1990, 14, 1-11.	1.4	8
335	New responsibilities for aged kinases in Bâ€lymphomas. Hematological Oncology, 2020, 38, 3-11.	1.7	8
336	Interleukin-15 Triggers the Proliferation and Cytotoxicity of Granular Lymphocytes in Patients With Lymphoproliferative Disease of Granular Lymphocytes. Blood, 1997, 89, 201-211.	1.4	8
337	Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. Blood, 1990, 76, 2080-5.	1.4	8
338	Synthesis and release of granulocyte-macrophage colony-stimulating factor by alveolar macrophages of patients with sarcoidosis. Sarcoidosis, 1993, 10, 147-8.	0.4	8
339	Current Concepts on Bronchoalveolar Lavage Cells in Extrinsic Allergic Alveolitis. Respiration, 1988, 54, 59-65.	2.6	7
340	Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment. Blood, 2021, 137, 2182-2195.	1.4	7
341	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood, 2000, 96, 647-654.	1.4	7
342	The immunological approach to the enigma of sarcoidosis. Sarcoidosis, 1984, 1, 24-35.	0.4	7

#	Article	IF	CITATIONS
343	Chemotactic cytokines: from the molecular level to clinical use. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 1998, 15, 131-3.	0.2	7
344	Defining TCRγδlymphoproliferative disorders by combined immunophenotypic and molecular evaluation. Nature Communications, 2022, 13, .	12.8	7
345	D cells with cytotoxic activity in acute lymphoblastic leukemia. Clinical Immunology and Immunopathology, 1980, 16, 238-244.	2.0	6
346	Non-T, non-B childhood acute lymphoblastic leukemia. Correlation between cytochemical markers and first complete remission. Cancer, 1984, 54, 981-985.	4.1	6
347	T-HELPER PHENOTYPE LEUKAEMIAS: ROLE OF HTLV-I. Lancet, The, 1985, 326, 1367-1368.	13.7	6
348	Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes. Leukemia Research, 1989, 13, 315-322.	0.8	6
349	Degradation of immobilized soluble elastin by tumor cells in culture: Quantitation by elisa. International Journal of Cancer, 1990, 46, 552-558.	5.1	6
350	Serum interleukin-2 receptor as index of tumor burden in hairy cell leukemia [letter; comment]. Blood, 1991, 77, 2540-2542.	1.4	6
351	Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2. Cancer, 1992, 69, 2525-2531.	4.1	6
352	Cellular Immunity in Sarcoidosis and Hypersensitivity Pneumonitis. Chest, 1993, 103, 139S-143S.	0.8	6
353	Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells. Cancer, 1994, 74, 2562-2569.	4.1	6
354	Lysis of pulmonary fibroblasts by lymphokine (ILâ€2)â€activated killer cellsâ€"a mechanism affecting the human lung microenvironment?. Clinical and Experimental Immunology, 1996, 105, 383-388.	2.6	6
355	Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation. British Journal of Haematology, 1999, 106, 119-127.	2.5	6
356	Telomerase Activity and Clinical Progression in Chronic Lymphoproliferative Disorders of B-Cell Lineage. Leukemia and Lymphoma, 2001, 41, 35-45.	1.3	6
357	Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. Expert Review of Anticancer Therapy, 2004, 4, 387-400.	2.4	6
358	High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 127-129.	3.0	6
359	Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. Hematological Oncology, 2018, 36, 366-369.	1.7	6
360	Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall. Human Pathology, 2018, 81, 131-137.	2.0	6

#	Article	IF	Citations
361	Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Human Pathology, 2019, 85, 251-259.	2.0	6
362	Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia. Oncotarget, 2018, 9, 32219-32231.	1.8	6
363	Transbronchial biopsy in sarcoidosis: the role of immunohistochemical analysis for granuloma detection. Sarcoidosis, 1992, 9, 95-100.	0.4	6
364	Increased levels of soluble interleukin-2 receptor in the serum of patients with human immunodeficiency virus infection. Diagnostic and Clinical Immunology, 1987, 5, 180-3.	0.3	6
365	Alpha-interferon activates the natural killer system in patients with hairy cell leukemia. Blood, 1986, 68, 293-6.	1.4	6
366	Interrogating molecular genetics to refine LGLL classification. Blood, 2022, 139, 3002-3004.	1.4	6
367	Impaired Gamma Interferon Production by Cells from Patients with Lymphoproliferative Disorders of Mature T and NK Cells. Scandinavian Journal of Immunology, 1985, 21, 315-320.	2.7	5
368	Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia. European Journal of Cancer & Clinical Oncology, 1989, 25, 1577-1581.	0.7	5
369	Global monitoring of influenza: potential contribution of national networks from a French perspective. Expert Review of Anti-Infective Therapy, 2006, 4, 387-393.	4.4	5
370	Immunohistochemical characterization of sarcoid granuloma: differentiation antigens and adhesion molecules. Sarcoidosis, 1991, 8, 171-2.	0.4	5
371	Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. Blood, 1990, 75, 1525-30.	1.4	5
372	Cellular immune responses in the lung of hypersensitivity pneumonitis. European Respiratory Journal, 1990, 3, 357-9.	6.7	5
373	Human retroviruses and their aetiological link to pulmonary diseases. European Respiratory Journal, 1993, 6, 925-9.	6.7	5
374	Immunoregulation in Farmer's Lung Disease. Chest, 1986, 89, 133S-135S.	0.8	4
375	Circulating soluble adhesion molecules: more observations on ICAM-1 in patients with Hodgkin's disease. Trends in Immunology, 1994, 15, 140-141.	7. 5	4
376	Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis. Current Signal Transduction Therapy, 2011, 6, 88-98.	0.5	4
377	Successful control of Blastoschizomyces capitatus infection in three consecutive acute leukaemia patients despite initial unresponsiveness to liposomal amphotericin B. Mycoses, 2011, 54, 365-369.	4.0	4
378	Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of <i>SF3B1</i> gene refines prognosis in treatment-naÃ-ve chronic lymphocytic leukemia. Haematologica, 2017, 102, e144-e147.	3.5	4

#	Article	IF	Citations
379	Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission. Journal of the Neurological Sciences, 2018, 392, 63-64.	0.6	4
380	Dabigatran in ibrutinibâ€treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. Hematological Oncology, 2018, 36, 801-803.	1.7	4
381	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. HemaSphere, 2020, 4, e395.	2.7	4
382	Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. Frontiers in Oncology, 2021, 11, 733848.	2.8	4
383	Cytotoxic in vitro function in the lymphoproliferative disease of granular lymphocytes. Clinical and Experimental Immunology, 1987, 70, 222-30.	2.6	4
384	N-Acetyl-Î ² -D-Glucosaminidase Activity in T Chronic Lymphocytic Leukaemia. Acta Haematologica, 1981, 66, 69-70.	1.4	3
385	B cells in chronic lymphocytic leukaemia comparative analysis of blood and bone marrow. Blut, 1984, 49, 69-73.	1,2	3
386	B-ly-7, a monoclonal antibody labeling of activated lung lymphocytes [letter]. Blood, 1991, 77, 1855-1856.	1.4	3
387	Prognostic significance of soluble CD8 serum levels in HIV-1 infection. Aids, 1992, 6, 133.	2.2	3
388	The raft marker GM1 identifies functional subsets of granular lymphocytes in patients with CD3+ lymphoproliferative disease of granular lymphocytes. Leukemia, 2004, 18, 771-776.	7.2	3
389	CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients. Leukemia, 2005, 19, 1099-1101.	7.2	3
390	Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy. European Journal of Haematology, 2016, 96, 586-592.	2.2	3
391	Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics―Research. Frontiers in Oncology, 2020, 10, 802.	2.8	3
392	Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?. Frontiers in Oncology, 2020, 10, 613570.	2.8	3
393	The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients. Dentistry Journal, 2021, 9, 11.	2.3	3
394	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. Blood, 1997, 90, 1115-1123.	1.4	3
395	Bias toward use of T-cell receptor variable regions in the lung: research tool or clinically useful technique?. European Respiratory Journal, 1997, 10, 767-9.	6.7	3
396	Hairy cell sensitivity to the lysis in vitro. Cancer Immunology, Immunotherapy, 1989, 30, 254-256.	4.2	2

#	Article	IF	CITATIONS
397	High Serum Levels of Soluble Interleukin-2 Receptor and Absence of Detectable Levels of Soluble CD30 Molecule: A Specific Diagnostic Combination for Hairy Cell Leukemia. Leukemia and Lymphoma, 1992, 6, 385-388.	1.3	2
398	Determinants of HIV disease progression. Lancet, The, 1992, 339, 130.	13.7	2
399	CD5+ Leukemic Monocytoid B-cell Lymphoma and Lymphocytic Lymphomas. American Journal of Clinical Pathology, 1993, 100, 187-188.	0.7	2
400	Right Atrial Mass in a Patient With T-Cell Chronic Lymphocytic Leukemia. Circulation, 2007, 116, e569-72.	1.6	2
401	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 592-598.	0.4	2
402	A case of "double hit―mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. Annals of Hematology, 2020, 99, 2715-2717.	1.8	2
403	T cell subpopulations in B cell chronic lymphocytic leukaemias. Clinical and Experimental Immunology, 1984, 57, 752-4.	2.6	2
404	Immunological features in chronic lymphocytic leukaemia (CLL) of T cell origin. Journal of Clinical & Laboratory Immunology, 1979, 2, 45-50.	0.1	2
405	Stimulation induced by autologous lymphocyte subpopulations from healthy subjects in mixed lymphocyte reaction (MLR). Transplantation Proceedings, 1979, 11, 1373-4.	0.6	2
406	Serum interleukin-2 receptor as index of tumor burden in hairy cell leukemia. Blood, 1991, 77, 2540-2.	1.4	2
407	The clinical use of BAL in patients with pulmonary infections. European Respiratory Journal, 1990, 3, 954-5, 961-9.	6.7	2
408	B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation. Cancer, 2000, 89, 1259-68.	4.1	2
409	Cultured T Cells from Patients with T Cell Chronic Lymphocytic Leukemia Demonstrate a Normal Phenotype. Immunobiology, 1985, 169, 186-197.	1.9	1
410	Conjunctival Biopsy in Sarcoidosis. American Journal of Ophthalmology, 1985, 100, 347-348.	3.3	1
411	Granuloma Formation. , 2007, , 87-100.		1
412	The Italian Society of Immunology: past, present and future. European Journal of Immunology, 2010, 40, 2664-2666.	2.9	1
413	Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy. American Journal of Hematology, 2015, 90, E135-E137.	4.1	1
414	A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e629-e644.	0.4	1

#	Article	IF	Citations
415	Evaluation of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 5563-5563.	1.4	1
416	Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood, 1993, 81, 2723-2727.	1.4	1
417	Human Immunodeficiency Virus and the Lung. , 1998, , 141-165.		1
418	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. Blood, 2020, 136, 33-34.	1.4	1
419	Immunohistochemical detection of microenvironmental abnormalities in lung biopsies from patients with sarcoidosis. Sarcoidosis, 1993, 10, 152-3.	0.4	1
420	Immunology of Extrapulmonary Sarcoid Lesions. Seminars in Respiratory and Critical Care Medicine, 1992, 13, 380-392.	2.1	0
421	Prognostic Factors in Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance. Leukemia and Lymphoma, 2002, 43, 1713-1714.	1.3	O
422	Why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood, 2002, 99, 1876-1878.	1.4	0
423	SYSTEMIC DISEASE Sarcoidosis. , 2006, , 196-202.		O
424	P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome. Leukemia Research, 2009, 33, S103.	0.8	0
425	Serum vascular endothelial growth factor (VEGF) in the differential diagnosis of amyloid neuropathy and POEMS syndrome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 106-108.	3.0	O
426	P160Three-dimensional left ventricular global longitudinal strain is as feasible and accurate as two-dimensional global longitudinal strain for subclinical cardiotoxicity surveillance. European Heart Journal, 2017, 38, .	2.2	0
427	Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. Annals of Hematology, 2018, 97, 2001-2003.	1.8	O
428	Large Granular Lymphocyte Leukemia. Hematologic Malignancies, 2021, , 231-246.	0.2	0
429	Lymphocytes., 2002,, 119-130.		O
430	Bronchiolar Epithelium in Idiopathic Pulmonary Fibrosis/Usual Interstitial Fibrosis. Lung Biology in Health and Disease, 2003, , 631-664.	0.1	0
431	Lymphocytic Aspects. Lung Biology in Health and Disease, 2005, , 79-96.	0.1	0
432	Effects of CK2 Inhibition on Multiple Signaling Pathways in Myeloma Cells. Blood, 2008, 112, 5163-5163.	1.4	0

#	Article	IF	CITATIONS
433	Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2 Blood, 2009, 114, 3840-3840.	1.4	О
434	Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma. , 2012, , 87-108.		0
435	R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience. Blood, 2013, 122, 3042-3042.	1.4	O
436	Alveolar macrophages in HIV-1 infection express accessory molecules, activation markers, and release increased biological response modifiers. Chest, 1993, 103, 108S-111.	0.8	0
437	Clonal studies of CD3- lymphoproliferative disease of granular lymphocytes. Blood, 1993, 81, 2363-2368.	1.4	O
438	HSP70-HSF1 Interplays Has a Role in the Pathogenesis of Chronic Lymphocytic Leukemia and Is a Druggable Target. Blood, 2016, 128, 4368-4368.	1.4	0
439	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. Blood, 2020, 136, 30-31.	1.4	O
440	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. Blood, 2020, 136, 49-50.	1.4	0